Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria

• Published in: Archives of Dermatological Research Vol. 316; no. 6; p. 261
• Main Authors: Hoşgören-Tekin, Selcen, Eyüboğlu, İrem Peker, Akkiprik, Mustafa, Giménez-Arnau, Ana Maria, Salman, Andaç
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 25-05-2024; Springer Nature B.V
• Subjects: Adult; Anti-Allergic Agents - administration & dosage; Anti-Allergic Agents - therapeutic use; Case-Control Studies; Chronic Urticaria - blood; Chronic Urticaria - drug therapy; Chronic Urticaria - immunology; Cytokines; Cytokines - blood; Dermatology; Disease control; Drug delivery; Female; Humans; Immunoglobulin E; Inflammation; Interleukin 4; Interleukin 5; Lymphocytes T; Male; Medicine; Medicine & Public Health; Middle Aged; Monoclonal antibodies; Omalizumab - administration & dosage; Omalizumab - therapeutic use; Original Paper; Plasma levels; Severity of Illness Index; Treatment Outcome; Urticaria; Young Adult; Treatment; Cytokine; IL-17; Omalizumab; IL-4; IL-5; IL-33; IL-10
• ISSN: 1432-069X; 0340-3696; 1432-069X
• DOI: 10.1007/s00403-024-02966-6

While several studies have examined the role of T cells and related cytokines in the development of chronic spontaneous urticaria (CSU), there is a limited amount of research focusing on the changes in cytokine levels during omalizumab treatment. The primary objective of this study was to investigate the inflammatory cytokine profile (including IL-4, IL-5, IL-10, IL-13, IL-17, IL-31, IL-33, and TNFα) among CSU patients undergoing to omalizumab treatment. Plasma levels of cytokines were measured using ELISA. Measurements were taken before CSU treatment, at the 3rd and 6th months of omalizumab treatment, and once in the control group. The severity of the patients’ disease was assessed using the weekly Urticaria Activity Score(UAS7), and disease control was evaluated using the Urticaria Control Test(UCT). Thirty-one CSU patients and 56 age- and gender-matched healthy controls were included. Plasma levels of IL-4 and IL-33 were significantly lower in patients with CSU compared to healthy controls (
p
 = 0.001;
p
 = 0.038, respectively). During omalizumab treatment, IL-4 levels showed a significant increase in the 3rd month compared to baseline (
p
 = 0.01), and IL-5 levels significantly decreased in the 6th month compared to both the 3rd month and baseline (6th month vs. baseline;
p
 = 0.006, 6th month vs. 3rd month;
p
 = 0.001). One potential mechanism of action for omalizumab may involve its regulatory effects on type 2 inflammatory cytokines in CSU patients. This finding partially explains the efficacy of anti-IL-4/13 treatments in chronic spontaneous urticaria. Further investigations on drugs targeting type 2 inflammatory cytokines in CSU are warranted.